Research graph
References from Rac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41588-021-00874-3
10.1038/s41588-021-00874-3 · External reference
10.1093/neuonc/nop020
10.1093/neuonc/nop020 · External reference
10.1016/j.dnarep.2010.09.018
10.1016/j.dnarep.2010.09.018 · External reference
10.1093/jnci/djaa095
10.1093/jnci/djaa095 · External reference
Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer
10.1016/j.ijrobp.2016.10.018 · 2017 · External reference
10.1186/s12943-023-01801-2
10.1186/s12943-023-01801-2 · External reference
10.1158/1541-7786.mcr-11-0312
10.1158/1541-7786.mcr-11-0312 · External reference
10.1158/0008-5472.can-04-4202
10.1158/0008-5472.can-04-4202 · External reference
10.1158/1535-7163.mct-19-0734
10.1158/1535-7163.mct-19-0734 · External reference
10.1126/sciadv.aat1719
10.1126/sciadv.aat1719 · External reference
10.1158/1535-7163.mct-20-0502
10.1158/1535-7163.mct-20-0502 · External reference
10.1158/1078-0432.ccr-23-1129/731522/am/a-phase-ib-study-of-the-dna-pk-inhibitor
10.1158/1078-0432.ccr-23-1129/731522/am/a-phase-ib-study-of-the-dna-pk-inhibitor · External reference
A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors
10.1016/j.ijrobp.2023.09.024 · 2024 · External reference
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
10.1001/jamaoncol.2022.5074 · 2022 · External reference
10.1038/s41586-020-2363-0
10.1038/s41586-020-2363-0 · External reference
10.1038/s41467-020-17512-x
10.1038/s41467-020-17512-x · External reference
10.1158/0008-5472.can-16-2008
10.1158/0008-5472.can-16-2008 · External reference
10.1016/j.cell.2023.11.022
10.1016/j.cell.2023.11.022 · External reference
10.3390/cancers11091231
10.3390/cancers11091231 · External reference
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
10.1186/s40170-024-00341-7 · 2024 · External reference
10.1038/s41586-025-09460-7
10.1038/s41586-025-09460-7 · External reference
10.1158/2159-8290.cd-23-0437
10.1158/2159-8290.cd-23-0437 · External reference
10.1089/ars.2022.0085
10.1089/ars.2022.0085 · External reference
Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection
10.1177/01945998211013765 · 2022 · External reference
Tumor Hypoxia and CD8(+) T-Cell Infiltration in Patients With Advanced Laryngeal Cancer
10.1002/ohn.1291 · 2025 · External reference
10.1016/j.molcel.2018.06.002
10.1016/j.molcel.2018.06.002 · External reference
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
10.1021/acs.jmedchem.5c03767 · 2026 · External reference
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
10.1182/blood.2025031201 · 2026 · External reference
10.1002/anbr.202300074
10.1002/anbr.202300074 · External reference
10.1158/1535-7163.mct-21-0348
10.1158/1535-7163.mct-21-0348 · External reference
10.1158/1535-7163.mct-23-0803
10.1158/1535-7163.mct-23-0803 · External reference
10.1158/1535-7163.c.8687979
10.1158/1535-7163.c.8687979 · External reference
10.1038/nprot.2006.5
10.1038/nprot.2006.5 · External reference
10.2307/3576448
10.2307/3576448 · External reference
10.1016/s0304-3835(98)00292-4
10.1016/s0304-3835(98)00292-4 · External reference
Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation
2001 · External reference
10.1056/nejmoa0912217
10.1056/nejmoa0912217 · External reference
Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42
10.1158/2767-9764.crc-22-0303 · 2022 · External reference
10.1038/s41586-022-05575-3
10.1038/s41586-022-05575-3 · External reference
The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity
10.1038/s41467-024-48076-9 · 2024 · External reference
10.1158/0008-5472.can-20-0057
10.1158/0008-5472.can-20-0057 · External reference
10.1124/jpet.109.154997
10.1124/jpet.109.154997 · External reference
10.1074/jbc.m303795200
10.1074/jbc.m303795200 · External reference
Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
10.1038/s41419-020-02885-0 · 2020 · External reference
10.1038/nrm1493
10.1038/nrm1493 · External reference
10.1038/ncb1212
10.1038/ncb1212 · External reference
10.1158/1538-7445.am2013-4791
10.1158/1538-7445.am2013-4791 · External reference
10.1093/jnci/90.13.978
10.1093/jnci/90.13.978 · External reference
10.1634/theoncologist.7-6-492
10.1634/theoncologist.7-6-492 · External reference
10.4161/cc.10.24.18661
10.4161/cc.10.24.18661 · External reference
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
10.1186/s13046-019-1434-2 · 2019 · External reference
10.1038/onc.2016.163
10.1038/onc.2016.163 · External reference
A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer
10.1016/j.xcrm.2025.102233 · 2025 · External reference
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
10.1001/jamaoncol.2022.5074 · ExternalCitation · doi-reference
10.1002/anbr.202300074
10.1002/anbr.202300074 · ExternalCitation · doi-reference
Tumor Hypoxia and CD8(+) T-Cell Infiltration in Patients With Advanced Laryngeal Cancer
10.1002/ohn.1291 · ExternalCitation · doi-reference
10.1016/j.cell.2023.11.022
10.1016/j.cell.2023.11.022 · ExternalCitation · doi-reference
10.1016/j.dnarep.2010.09.018
10.1016/j.dnarep.2010.09.018 · ExternalCitation · doi-reference
Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer
10.1016/j.ijrobp.2016.10.018 · ExternalCitation · doi-reference
A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors
10.1016/j.ijrobp.2023.09.024 · ExternalCitation · doi-reference
10.1016/j.molcel.2018.06.002
10.1016/j.molcel.2018.06.002 · ExternalCitation · doi-reference
A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer
10.1016/j.xcrm.2025.102233 · ExternalCitation · doi-reference
10.1016/s0304-3835(98)00292-4
10.1016/s0304-3835(98)00292-4 · ExternalCitation · doi-reference
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
10.1021/acs.jmedchem.5c03767 · ExternalCitation · doi-reference
10.1038/ncb1212
10.1038/ncb1212 · ExternalCitation · doi-reference
10.1038/nprot.2006.5
10.1038/nprot.2006.5 · ExternalCitation · doi-reference
10.1038/nrm1493
10.1038/nrm1493 · ExternalCitation · doi-reference
10.1038/onc.2016.163
10.1038/onc.2016.163 · ExternalCitation · doi-reference
Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
10.1038/s41419-020-02885-0 · ExternalCitation · doi-reference
10.1038/s41467-020-17512-x
10.1038/s41467-020-17512-x · ExternalCitation · doi-reference
The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity
10.1038/s41467-024-48076-9 · ExternalCitation · doi-reference
10.1038/s41586-020-2363-0
10.1038/s41586-020-2363-0 · ExternalCitation · doi-reference
10.1038/s41586-022-05575-3
10.1038/s41586-022-05575-3 · ExternalCitation · doi-reference
10.1038/s41586-025-09460-7
10.1038/s41586-025-09460-7 · ExternalCitation · doi-reference
10.1038/s41588-021-00874-3
10.1038/s41588-021-00874-3 · ExternalCitation · doi-reference
10.1056/nejmoa0912217
10.1056/nejmoa0912217 · ExternalCitation · doi-reference
10.1074/jbc.m303795200
10.1074/jbc.m303795200 · ExternalCitation · doi-reference
10.1089/ars.2022.0085
10.1089/ars.2022.0085 · ExternalCitation · doi-reference
10.1093/jnci/90.13.978
10.1093/jnci/90.13.978 · ExternalCitation · doi-reference
10.1093/jnci/djaa095
10.1093/jnci/djaa095 · ExternalCitation · doi-reference
10.1093/neuonc/nop020
10.1093/neuonc/nop020 · ExternalCitation · doi-reference
10.1124/jpet.109.154997
10.1124/jpet.109.154997 · ExternalCitation · doi-reference
10.1126/sciadv.aat1719
10.1126/sciadv.aat1719 · ExternalCitation · doi-reference
10.1158/0008-5472.can-04-4202
10.1158/0008-5472.can-04-4202 · ExternalCitation · doi-reference
10.1158/0008-5472.can-16-2008
10.1158/0008-5472.can-16-2008 · ExternalCitation · doi-reference
10.1158/0008-5472.can-20-0057
10.1158/0008-5472.can-20-0057 · ExternalCitation · doi-reference
10.1158/1078-0432.ccr-23-1129/731522/am/a-phase-ib-study-of-the-dna-pk-inhibitor
10.1158/1078-0432.ccr-23-1129/731522/am/a-phase-ib-study-of-the-dna-pk-inhibitor · ExternalCitation · doi-reference
10.1158/1535-7163.c.8687979
10.1158/1535-7163.c.8687979 · ExternalCitation · doi-reference
10.1158/1535-7163.mct-19-0734
10.1158/1535-7163.mct-19-0734 · ExternalCitation · doi-reference
10.1158/1535-7163.mct-20-0502
10.1158/1535-7163.mct-20-0502 · ExternalCitation · doi-reference
10.1158/1535-7163.mct-21-0348
10.1158/1535-7163.mct-21-0348 · ExternalCitation · doi-reference
10.1158/1535-7163.mct-23-0803
10.1158/1535-7163.mct-23-0803 · ExternalCitation · doi-reference
10.1158/1538-7445.am2013-4791
10.1158/1538-7445.am2013-4791 · ExternalCitation · doi-reference
10.1158/1541-7786.mcr-11-0312
10.1158/1541-7786.mcr-11-0312 · ExternalCitation · doi-reference
10.1158/2159-8290.cd-23-0437
10.1158/2159-8290.cd-23-0437 · ExternalCitation · doi-reference
Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42
10.1158/2767-9764.crc-22-0303 · ExternalCitation · doi-reference
Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection
10.1177/01945998211013765 · ExternalCitation · doi-reference
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
10.1182/blood.2025031201 · ExternalCitation · doi-reference
10.1186/s12943-023-01801-2
10.1186/s12943-023-01801-2 · ExternalCitation · doi-reference
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
10.1186/s13046-019-1434-2 · ExternalCitation · doi-reference
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma
10.1186/s40170-024-00341-7 · ExternalCitation · doi-reference
10.1634/theoncologist.7-6-492
10.1634/theoncologist.7-6-492 · ExternalCitation · doi-reference
10.2307/3576448
10.2307/3576448 · ExternalCitation · doi-reference
10.3390/cancers11091231
10.3390/cancers11091231 · ExternalCitation · doi-reference
10.4161/cc.10.24.18661
10.4161/cc.10.24.18661 · ExternalCitation · doi-reference
